No Data
No Data
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
X4 Pharmaceuticals Unveils Corporate Presentation for Investors
X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress
No Data
No Data